Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFIKIR: Lirilumab Maintenance in Elderly AML
NCT01687387Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- Oct 2012
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lirilumab in acute myeloid leukemia (AML) (3 arms), sponsored by Innate Pharma. Primary endpoint: Leukemia-Free Survival at 48 months. Started Oct 2012; status: completed.
02
Drugs
lirilumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01687387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01687387.